Drugs / Sonesitatug Vedotin
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04805307 | Dec 2020 → Apr 2024 | gastric carcinoma, malignant pancreatic neoplasm | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07143604 | Aug 2025 → Aug 2026 overdue | gastric cancer, gastroesophageal junction adenocarcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07069712 | Jul 2025 → Nov 2027 expected | gastroesophageal adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT06630130 | Jan 2025 → Oct 2028 expected | gastric cancer | Jeeyun Lee | Recruiting | No outcome recorded |
| Phase 2 | NCT06219941 | Dec 2023 → Nov 2026 expected | biliary tract cancer, gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT05702229 | Jan 2023 → Nov 2027 expected | gastric cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07431281 | Feb 2026 → Aug 2029 expected | esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06346392 | Mar 2024 → May 2026 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | AstraZeneca | Active not recruiting | Mixed |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-07-28 | Keymed Biosciences Co.Ltd | Results CLDN18.2 ADC CMG901：首个全球范围III期取得积极顶线结果，总生存期获益显著 keymedbio.com ↗
CLARITY-Gastric01全球III期临床试验公布的积极顶线结果显示，与研究者选择的治疗方案相比，CMG901在二线及后线CLDN18.2阳性晚期胃癌患者中展现出具有统计学显著性且极具临床意义的OS改善。 |
| 2026-07-27 | AstraZeneca | Results Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers astrazeneca.com ↗ |
| 2024-02-24 | Keymed Biosciences Co.Ltd | Results 疗效优异：靶向Claudin 18.2抗体偶联药物CMG901 I期临床研究最新数据亮相ASCO年会 keymedbio.com ↗
研究结果显示，CMG901具有良好的安全性和耐受性，在治疗晚期Claudin 18.2高表达胃癌/胃食管结合部腺癌受试者中表现出了优秀的疗效 |
| 2023-07-24 | Keymed Biosciences Co.Ltd | Results CMG901 I期临床研究数据最新结果在ASCO Plenary Series以口头报告形式公布 keymedbio.com ↗
89例可评估的Claudin 18.2阳性胃癌或胃食管结合部腺癌患者在三个剂量组的确认的客观缓解率（ORR）为33%，确认的疾病控制率（DCR）为70%。 |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-22 | Keymed Biosciences Co.Ltd | 2026 ESMO | 康诺亚CLDN18.2 ADC CMG901 III期临床研究成果入选突破性摘要，将于主席研讨会公布 keymedbio.com ↗ |
| 2026-07-28 | Keymed Biosciences Co.Ltd | CLDN18.2 ADC CMG901：首个全球范围III期取得积极顶线结果，总生存期获益显著 keymedbio.com ↗ |
| 2026-07-27 | AstraZeneca | Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers astrazeneca.com ↗ |
| 2024-02-24 | Keymed Biosciences Co.Ltd | 疗效优异：靶向Claudin 18.2抗体偶联药物CMG901 I期临床研究最新数据亮相ASCO年会 keymedbio.com ↗ |
| 2023-07-24 | Keymed Biosciences Co.Ltd | CMG901 I期临床研究数据最新结果在ASCO Plenary Series以口头报告形式公布 keymedbio.com ↗ |
| 2023-03-30 | AstraZeneca | License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed astrazeneca.com ↗ |
| 2023-02-23 | AstraZeneca | AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate astrazeneca.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sonesitatug vedotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07431281 ↗ |
| Known as | AZD0901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07143604 ↗ |
| Known as | CMG901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04805307 ↗ |
| Known as | Sone-Ve | “Sonesitatug Vedotin(Sone-Ve) 2.2mg /kg IV on D1, Q3W for 3 cycles” NCT06630130 ↗ |
| Known as | Sonesitatug vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068297 ↗ |
| Known as | Sonesitatug vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068297 ↗ |
| Modality | Other / unclassified | “an anti Claudin18.2 ADC; IV infusion” NCT05702229 ↗ |
| Route | Intravenous | “CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle.” NCT04805307 ↗ |
| Target | CLDN18 | “Claudin 18.2-targeting antibody-drug conjugate CMG901” PMID 39788133 ↗ Jan 2025 |